eTheRNA mRNA immunotherapies for oncology and infectious diseases. Sector: Healthcare. Country: Belgium. Fund: LSP 5 Entry 2016.

John is a Partner at EQT Life Sciences, formerly LSP. He currently serves on the boards of etherna, ONWARD Medical, VarmX, Visus Therapeutics and Xilis. He ...

23 авг. 2022 г. · eTheRNA's new business model will utilize this suite of capabilities to provide superior products for partners in both early-stage research as ...

27 авг. 2022 г. · eTheRNA, a Niel, Belgium-based mRNA technologies company, raised €39M in a Series B2 financing. The round was led by Novalis LifeSciences.

24 авг. 2022 г. · Moderna co-founder Kenneth Chien and Novalis LifeSciences LLC are the lead investors of a €39m Series B2 financing in eTheRNA.

Future-proof companies and make a positive impact. EQT invests in good companies with a mission to help them develop into great and sustainable companies.

The Group will invest EUR9 million in eTheRNA after relevant conditions being fulfilled as agreed in the Investment Agreement. Upon the completion of the equity ...

24 авг. 2022 г. · The Belgian mRNA technologies company eTheRNA has raised €39 million ($38.7 million) in a series B2 financing and gained new board members.

eTheRNA (the Company), a leading mRNA technologies company, announced today that it has raised €39M in a Series B2 financing to expand investment in its ...

eTheRNA announced it has entered into a strategic cooperation and product license agreement with China Grand Pharmaceutical & Healthcare Holdings Ltd.